Prospective Measurement of Post-Treatment Lymphedema

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
M.D. Anderson Cancer Center Identifier:
First received: July 2, 2007
Last updated: July 22, 2013
Last verified: July 2013

July 2, 2007
July 22, 2013
May 2006
May 2015   (final data collection date for primary outcome measure)
Number of incidences of lymphedema following surgical treatment of stage I, II, and III cutaneous malignant melanoma [ Time Frame: 30 Month Period ] [ Designated as safety issue: No ]
Not Provided
Complete list of historical versions of study NCT00495950 on Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
Prospective Measurement of Post-Treatment Lymphedema
Prospective Measurement of Post-Treatment Lymphedema in Patients With Melanoma

The goal of this study is to measure the amount of limb swelling (lymphedema) that sometimes occurs after melanoma treatment, and to find out how people feel and react to the diagnosis and treatment of melanoma.

If you choose to take part in this study, you will have measurements taken of your arms or legs using a Perometer and a bioimpedance machine. The Perometer is a machine that painlessly measures the fluid in your limb using two-directional infrared lights. These lights are located in the frame of the machine that encircles the arm or leg during the measurement. The bioimpedance is a machine that measures the fluid in your arm or leg by passing a very small current through the body similar to an electrocardiogram (EKG). These very small currents are located in electrodes that are placed on the hands and feet during the measurement. Both machines are able to pick up changes in limb size.

You will also be asked to complete a set of questionnaires relating to any symptoms that you may experience in your limbs and/or trunk (chest, stomach, and hip areas) during and following your standard cancer treatment.

Additional questionnaires, along with your limb measurements, will be done at your regularly-scheduled follow-up clinic visits, 3-6 months, 9-12 months, 15-18 months, 21-24 months and 27- 30 months. You will complete the additional questionnaires using a laptop computer or a hardcopy. The measurements and questionnaires will take 45-60 minutes to complete each time.

Some of the data from this study may be sent to the University of Missouri for analysis. The data that is sent will not have any personal identifiers. Researchers at University of Missouri will not be able to link the data to the protected health information or personal identity of any individual participant.

This is an investigational study. Up to 350 patients will take part in this study. All patients will be enrolled at MD Anderson.

Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

Study participants with a confirmed diagnosis (M.D. Anderson pathology) of invasive cutaneous melanoma (stages I-III).

Behavioral: Questionnaire
Questionnaires relating to symptoms experienced during and following standard cancer treatment.
Other Name: Survey
Intervention: Behavioral: Questionnaire
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Active, not recruiting
Not Provided
May 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Patients with a confirmed diagnosis (M.D. Anderson pathology) of invasive cutaneous melanoma (stages I-III) will be recruited for participation as they present for their initial clinical evaluation to the University of Texas M.D. Anderson Melanoma and Skin Center.
  2. Prior to surgical treatment
  3. Patients who can knowledgeably and voluntarily provide an informed consent to participate. The informed consent will be signed and dated.
  4. Fluent in English.
  5. At least 18 years of age.

Exclusion Criteria:

  1. Patients with a prior history of lymphedema or melanoma prior to treatment.
  2. Patients who are unable to consent due to other medical illnesses or disorientation to person, place or time.
  3. Patients with known distant metastatic disease (Stage IV).
  4. Patients with implanted device (pace maker), orthopedic implants, and metal frames.
  5. Presence of concurrent malignancy that requires active treatment, such as chemotherapy or biotherapy, prior to enrollment.
18 Years and older
Contact information is only displayed when the study is recruiting subjects
United States
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Not Provided
Principal Investigator: Janice N. Cormier, MD M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
July 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP